A recent retrospective study reported generally unsatisfactory outcomes with immunotherapy in NSCLC patients harboring BRAF alterations, although class 2 and 3 altered patients achieved numerically higher objective response rate (ORR) than those carrying class 1 mutations (26% vs. 9%; p = 0.25) [55]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.